Published in Circulation on November 26, 2002
Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (2005) 2.47
Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. Circulation (2015) 2.12
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol (2010) 1.57
Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart (2009) 1.54
The impact of 6 weeks of atrial fibrillation on left atrial and ventricular structure and function. J Thorac Cardiovasc Surg (2015) 1.41
Metabolic stress, reactive oxygen species, and arrhythmia. J Mol Cell Cardiol (2011) 1.26
Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis (2006) 1.25
Early determinants of H2O2-induced endothelial dysfunction. Free Radic Biol Med (2006) 1.22
Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol (2013) 1.14
S-Nitrosylation of cardiac ion channels. J Cardiovasc Pharmacol (2009) 1.12
Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal (2013) 1.07
Nitric oxide synthases in heart failure. Antioxid Redox Signal (2012) 1.07
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm (2008) 1.03
Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int (2014) 1.03
Redox regulation, NF-kappaB, and atrial fibrillation. Antioxid Redox Signal (2009) 1.01
Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol (2015) 0.99
Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep (2012) 0.93
Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Front Physiol (2012) 0.88
Nitric oxide synthases and atrial fibrillation. Front Physiol (2012) 0.88
Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke (2016) 0.87
Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol (2015) 0.87
Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol (2011) 0.85
Atrial fibrillation: effects beyond the atrium? Cardiovasc Res (2015) 0.84
[New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers]. Herzschrittmacherther Elektrophysiol (2006) 0.83
Atrial Fibrillation Is Associated with a Marker of Endothelial Function and Oxidative Stress in Patients with Acute Myocardial Infarction. PLoS One (2015) 0.82
Attenuation of acetylcholine activated potassium current (I KACh) by simvastatin, not pravastatin in mouse atrial cardiomyocyte: possible atrial fibrillation preventing effects of statin. PLoS One (2014) 0.82
Histological and Biochemical Comparisons between Right Atrium and Left Atrium in Patients with Mitral Valvular Atrial Fibrillation. Korean Circ J (2014) 0.82
Compromised redox homeostasis, altered nitroso-redox balance, and therapeutic possibilities in atrial fibrillation. Cardiovasc Res (2016) 0.82
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model. J Korean Med Sci (2013) 0.81
Antioxidant therapies for the management of atrial fibrillation. Cardiovasc Diagn Ther (2012) 0.80
NADPH oxidase 4 induces cardiac arrhythmic phenotype in zebrafish. J Biol Chem (2014) 0.80
Melatonin-based therapeutics for neuroprotection in stroke. Int J Mol Sci (2013) 0.79
Assessment of left and right atrial 3D hemodynamics in patients with atrial fibrillation: a 4D flow MRI study. Int J Cardiovasc Imaging (2016) 0.78
[Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications]. Z Kardiol (2004) 0.78
The impacts of C-reactive protein and atrial fibrillation on carotid atherosclerosis and ischemic stroke in patients with suspected ischemic cerebrovascular disease: a single-center retrospective observational cohort study. Korean Circ J (2013) 0.77
eNOS3 Genetic Polymorphism Is Related to Post-Ablation Early Recurrence of Atrial Fibrillation. Yonsei Med J (2015) 0.77
Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation. Cardiovasc Res (2013) 0.77
Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol (2014) 0.77
Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. Sci Transl Med (2016) 0.76
Pulling on my heartstrings: mechanotransduction in cardiac development and function. Curr Opin Hematol (2016) 0.76
NO hope for patients with atrial fibrillation. Circulation (2002) 0.76
Simvastatin attenuates the oxidative stress, endothelial thrombogenicity and the inducibility of atrial fibrillation in a rat model of ischemic heart failure. Int J Mol Sci (2014) 0.76
Xanthine oxidase and uric Acid in atrial fibrillation. Front Physiol (2012) 0.76
A Circulating Biomarker Risk-Prediction Model Correlates with CHADS-2 Risk Score in Chronic Atrial Fibrillation. IJC Metab Endocr (2015) 0.75
Upregulation of sestrins protect atriums against oxidative damage and fibrosis in human and experimental atrial fibrillation. Sci Rep (2017) 0.75
Platelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation. Mediators Inflamm (2016) 0.75
Cardioembolic Stroke. Circ Res (2017) 0.75
Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study. Medicine (Baltimore) (2016) 0.75
Asymmetric Dimethylarginine Levels are Highly Associated With Atrial Fibrillation in an Elderly Population. Cardiol Res (2012) 0.75
Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. Am Heart J (2016) 0.75
Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. Sci Rep (2016) 0.75
Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Effect of physical exercise on platelet activity and the von-Willebrand-factor in patients with persistent lone atrial fibrillation. J Interv Card Electrophysiol (2004) 0.75
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med (2007) 7.69
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res (2007) 4.48
Pacing features that mimic malfunction: a review of current programmable and automated device functions that cause confusion in the clinical setting. J Cardiovasc Electrophysiol (2009) 4.19
Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem (2003) 3.23
Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension (2002) 3.23
Measurement of reactive oxygen species in cardiovascular studies. Hypertension (2007) 3.17
Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res (2010) 3.16
The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci (2003) 3.13
Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol (2002) 3.10
Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension (2009) 3.06
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol (2004) 2.94
Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation (2010) 2.93
Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm (2006) 2.81
Hands-on defibrillation: an analysis of electrical current flow through rescuers in direct contact with patients during biphasic external defibrillation. Circulation (2008) 2.80
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev (2011) 2.78
Role of extracellular superoxide dismutase in hypertension. Hypertension (2006) 2.74
Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med (2008) 2.68
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation (2007) 2.50
ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol (2004) 2.45
Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol (2008) 2.44
Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol (2010) 2.43
Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res (2010) 2.28
Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol (2011) 2.27
Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation (2004) 2.11
Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol (2003) 2.09
Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem (2003) 2.09
Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation (2004) 2.07
Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation (2005) 2.02
Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis (2005) 2.02
Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ Res (2007) 2.01
Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation (2011) 1.99
Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol (2008) 1.98
Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr (2002) 1.94
Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel. Circ Res (2007) 1.93
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest (2013) 1.92
Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90
Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. Circulation (2002) 1.90
Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. J Clin Invest (2015) 1.89
Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res (2009) 1.88
Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation (2002) 1.87
Cardiac Na+ current regulation by pyridine nucleotides. Circ Res (2009) 1.87
Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension (2009) 1.86
Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm (2011) 1.85
Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol (2002) 1.81
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol (2011) 1.80
The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation (2002) 1.72
Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem (2007) 1.72
Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol (2005) 1.72
Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res (2002) 1.68
Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation (2010) 1.68
A program encouraging early defibrillation results in improved in-hospital resuscitation efficacy. J Am Coll Cardiol (2004) 1.66
Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol (2005) 1.66
A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm (2006) 1.64
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol (2004) 1.64
Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol (2006) 1.64
Impact of race and gender on cardiac device implantations. Heart Rhythm (2007) 1.62
Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today (2006) 1.59
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol (2006) 1.59
Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J Physiol Heart Circ Physiol (2007) 1.57
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol (2010) 1.57
Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest (2015) 1.55
Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood) (2008) 1.55
Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med (2011) 1.54
Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm (2009) 1.54
NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem (2002) 1.53
A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells (2007) 1.53
The relationship of bipolar left ventricular pacing stimulus intensity to cardiac depolarization and repolarization in humans with cardiac resynchronization devices. J Cardiovasc Electrophysiol (2009) 1.51
Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: a potential mechanism underlying adult respiratory distress syndrome. Am J Pathol (2008) 1.51
Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation (2004) 1.50
Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation (2006) 1.50
Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol (2007) 1.47
The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ Res (2005) 1.46
Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation (2003) 1.45
Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol (2002) 1.44
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace (2010) 1.43
RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension (2006) 1.41
Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol Pharmacol (2003) 1.41
Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circ Res (2010) 1.40
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem (2003) 1.36
Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res (2013) 1.35
Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol (2002) 1.34
Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension (2012) 1.33
Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol (2010) 1.31
Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. Am J Physiol Heart Circ Physiol (2004) 1.29